EHD1 and cancer: These observations improve our understanding of how EHD1 impacts cancer development and progression and provide new insights into the underlying mechanisms of NSCLC angiogenesis, which emphasize that EHD1 is a potential antiangiogenic therapeutic target in NSCLC.